NCT06282874 2026-04-09
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
Guangdong Association of Clinical Trials
Phase 4 Active not recruiting
Clinical Trials
9 trialsNCT06007937 2026-04-08
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT03737994 2026-04-07
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06333899 2026-03-12
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Nationwide Children's Hospital
Phase EARLY_PHASE1 Recruiting
NCT06282991 2026-03-10
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled
Pfizer
Completed
NCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
NCT07415005 2026-02-17
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT06678555 2026-02-05
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
Pfizer
Active not recruiting
NCT05740943 2026-01-20
Induction Lorlatinib in Stage III Non-small Cell Lung Cancer
Guangdong Provincial People's Hospital
Phase 2 Active not recruiting